ResMed Inc. (LON:0KW4)

ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of GBP 29.84 billion. The enterprise value is 29.58 billion.

Market Cap	29.84B
Enterprise Value	29.58B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	Aug 14, 2025

Share Statistics

Current Share Class	146.41M
Shares Outstanding	n/a
Shares Change (YoY)	-0.14%
Shares Change (QoQ)	-0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.48M

Valuation Ratios

The trailing PE ratio is 29.19 and the forward PE ratio is 25.23.

PE Ratio	29.19
Forward PE	25.23
PS Ratio	7.95
PB Ratio	6.85
P/TBV Ratio	16.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.00, with an EV/FCF ratio of 24.39.

EV / Earnings	28.93
EV / Sales	7.77
EV / EBITDA	21.00
EV / EBIT	23.63
EV / FCF	24.39

Financial Position

The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.14.

Current Ratio	3.44
Quick Ratio	2.16
Debt / Equity	0.14
Debt / EBITDA	0.45
Debt / FCF	0.51
Interest Coverage	2,884.43

Financial Efficiency

Return on equity (ROE) is 25.86% and return on invested capital (ROIC) is 16.80%.

Return on Equity (ROE)	25.86%
Return on Assets (ROA)	14.02%
Return on Invested Capital (ROIC)	16.80%
Return on Capital Employed (ROCE)	23.58%
Revenue Per Employee	354,368
Profits Per Employee	96,452
Employee Count	10,600
Asset Turnover	0.68
Inventory Turnover	2.09

Taxes

In the past 12 months, ResMed has paid 202.07 million in taxes.

Income Tax	202.07M
Effective Tax Rate	16.50%

Stock Price Statistics

The stock price has increased by +16.12% in the last 52 weeks. The beta is 0.77, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+16.12%
50-Day Moving Average	270.77
200-Day Moving Average	244.92
Relative Strength Index (RSI)	42.01
Average Volume (20 Days)	129

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.71

Income Statement

In the last 12 months, ResMed had revenue of GBP 3.76 billion and earned 1.02 billion in profits. Earnings per share was 6.94.

Revenue	3.76B
Gross Profit	2.25B
Operating Income	1.23B
Pretax Income	1.22B
Net Income	1.02B
EBITDA	1.36B
EBIT	1.23B
Earnings Per Share (EPS)	6.94

Balance Sheet

The company has 882.78 million in cash and 621.74 million in debt, giving a net cash position of 261.04 million.

Cash & Cash Equivalents	882.78M
Total Debt	621.74M
Net Cash	261.04M
Net Cash Per Share	n/a
Equity (Book Value)	4.36B
Book Value Per Share	29.76
Working Capital	1.81B

Cash Flow

In the last 12 months, operating cash flow was 1.28 billion and capital expenditures -65.59 million, giving a free cash flow of 1.21 billion.

Operating Cash Flow	1.28B
Capital Expenditures	-65.59M
Free Cash Flow	1.21B
FCF Per Share	n/a

Margins

Gross margin is 59.99%, with operating and profit margins of 32.79% and 27.22%.

Gross Margin	59.99%
Operating Margin	32.79%
Pretax Margin	32.60%
Profit Margin	27.22%
EBITDA Margin	36.15%
EBIT Margin	32.79%
FCF Margin	32.29%

Dividends & Yields

This stock pays an annual dividend of 1.67, which amounts to a dividend yield of 0.59%.

Dividend Per Share	1.67
Dividend Yield	0.59%
Dividend Growth (YoY)	6.74%
Years of Dividend Growth	3
Payout Ratio	22.19%
Buyback Yield	0.14%
Shareholder Yield	0.74%
Earnings Yield	3.43%
FCF Yield	4.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.06 and a Piotroski F-Score of 7.

Altman Z-Score	12.06
Piotroski F-Score	7